Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
VA Medical Center, Houston Baylor College of Medicine |
---|---|
Information provided by: | VA Medical Center, Houston |
ClinicalTrials.gov Identifier: | NCT00304356 |
The purpose of this study is for compassionate use of nitazoxanide in the treatment of diarrheal disease due to Clostridium difficile infection when the patient has failed previous treatment with metronidazole or vancomycin.
Condition | Intervention | Phase |
---|---|---|
Clostridium Enterocolitis Pseudomembranous Colitis |
Drug: Nitazoxanide |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy |
Estimated Enrollment: | 100 |
Clostridium difficile is the leading cause of nosocomial diarrheal disease associated with antibiotic therapy. This is a debilitating condition with substantial morbidity and a mortality that may be around 2-3%. There has been an enormous increase in this disease at the VA Medical Center during the past two years, just as has occurred at other hospitals throughout the United States.
Currently recommended therapy for this condition is metronidazole, given orally. About 15-20% of patients fail to respond to initial therapy with metronidazole, and another 20% relapse after treatment. Relapses may be treated with another course of metronidazole; about one-half will respond to this therapy. The failures are treated with oral vancomycin, but this drug also has a failure rate of 10-20%. There is, at present, no other accepted therapy (although some articles in the literature favor vancomycin with ingested bacteria from benign species). Furthermore, there is a strong risk to the emergence of resistant bacteria when hospitalized patients are treated with oral vancomycin.
Nitazoxanide is an FDA approved drug that is marketed in the U.S. and has been widely used throughout the world to treat parasitic diseases of the gastrointestinal tract; several million children have been treated with this drug during the past decade. Nitazoxanide has been approved as an antiprotozoal agent for oral administration in pediatric patients, ages 1 through 11, with diarrhea. The drug acts by interfering with anaerobic metabolic pathways, and it has been shown to have excellent in vitro activity against C. difficile. We hypothesized that this drug was both safe and effective as an alternative in patients who have diarrheal disease caused by C. difficile. The IRB approved a double-blind protocol to compare metronidazole with nitazoxanide, and we have treated a total of 16 patients so far under this protocol.
In our IRB-approved double blind study (by design, two thirds of the subjects have been randomized to the nitazoxanide), our patients have appeared to have a good response rate -- so good, in fact, that we think that nitazoxanide may be a better drug to treat this infection than either metronidazole or vancomycin.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Nancy Logan, M.A. | 713-791-1414 ext 5455 | njarrar@bcm.tmc.edu |
United States, Texas | |
Baylor College of Medicine | Recruiting |
Houston, Texas, United States, 77030 | |
Principal Investigator: Daniel M Musher, M.D. | |
Michael E. Debakey VA Medical Center | Recruiting |
Houston, Texas, United States, 77030 | |
Principal Investigator: Daniel M Musher, M.D. | |
Sub-Investigator: Herbert L Dupont, MD | |
Sub-Investigator: Richard J Hamill, M.D. | |
Sub-Investigator: Arthur C White, M.D. | |
Sub-Investigator: Saima Aslam, M.D. | |
Sub-Investigator: Maria C Rodriguez-Barradas, M.D. |
Principal Investigator: | Daniel M Musher, M.D. | Baylor College of Medicine, Houston VA Medical Center |
Study ID Numbers: | H-15601 |
Study First Received: | March 16, 2006 |
Last Updated: | February 8, 2007 |
ClinicalTrials.gov Identifier: | NCT00304356 |
Health Authority: | United States: Institutional Review Board |
Clostridium difficile Associated Diarrhea |
Bacterial Infections Diarrhea Gastrointestinal Diseases Colonic Diseases Enterocolitis, Pseudomembranous Intestinal Diseases Enterocolitis |
Gram-Positive Bacterial Infections Digestive System Diseases Nitazoxanide Gastroenteritis Clostridium Infections Colitis |
Anti-Infective Agents Antiparasitic Agents Therapeutic Uses Pharmacologic Actions |